Erik Roy Hillesland, et al. v. Glenmark Pharmaceuticals, Inc. USA, et al.

[DO NOT PUBLISH]
In the
United States Court of Appeals
For the Eleventh Circuit
____________________
No. 23-14181
Non-Argument Calendar
____________________
IN RE: ZANTAC (RANITIDINE) PRODUCTS LIABILITY
LITIGATION
___________________________________________________
9:20-md-02924-RLR
ERIK ROY HILLESLAND,
Interested Party-Appellant,
versus
GLENMARK PHARMACEUTICALS, INC. USA,
APOTEX CORP.,
MICHAEL MCCANDLESS,
BRAD ALDRIDGE,
AJANTA PHARMA USA, INC., et al.,
Defendants-Appellees.
USCA11 Case: 23-14181 Document: 8-1 Date Filed: 02/23/2024 Page: 1 of 2

-- 1 of 2 --

2 Opinion of the Court 23-14181
____________________
Appeal from the United States District Court
for the Southern District of Florida
D.C. Docket No. 9:20-md-02924-RLR
____________________
Before L UCK , B RASHER, and ABUDU, Circuit Judges.
PER CURIAM:
This appeal is DISMISSED, sua sponte, for lack of jurisdic-
tion. As explained in our previous opinion dismissing appeal no.
23-11047, Appellant Erik Hillesland lacks standing to appeal be-
cause he did not properly become a plaintiff in this action. See Wolff
v. Cash 4 Titles, 351 F.3d 1348, 1353-54 (11th Cir. 2003) (explaining
that litigants must establish their standing to appeal, and only a lit-
igant who is aggrieved by a judgment or order may appeal); Marino
v. Ortiz, 484 U.S. 301, 304 (1988) (noting that in general, only par-
ties or those who properly become parties may appeal).
No petition for rehearing may be filed unless it complies
with the timing and other requirements of 11th Cir. R. 40-3 and all
other applicable rules.
USCA11 Case: 23-14181 Document: 8-1 Date Filed: 02/23/2024 Page: 2 of 2

-- 2 of 2 --